European Pharmaceutical Review: Compulsory licenses in Germany

Head of EIP’s Düsseldorf office, Christof Höhne, outlines the implications of Germany’s compulsory licensing in an article for the latest issue of the European Pharmaceutical Review. Two recent, high-profile pharmaceutical cases which have set the course for the future of German IP law are analysed by Christof, who highlights the advantages and disadvantages faced by both parties in a licensing negotiation.

The article can be read on the European Pharmaceutical Review website here.